Summary

The M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.

Bigpharma M&A activity during 2011
Top M&A deals by value in 2011
Most active dealmakers 2011
Comprehensive coverage of every deal announced in 2011

Description

The M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.

Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the M&A deals announced worldwide.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of M&A trends in 2011. The key M&A deals of 2011 are reviewed, as well as forecasts for dealmaking in 2012.

Chapter 3 analyzes the most active dealmakers in M&A during 2011.

Chapter 4 provides an overview of the leading deals for 2011 by headline value. The chapter provides covers M&A dealmaking during the year.

The main body of the report is provided in chapters 5 and 6.

Chapter 5 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company’s dealmaking during 2011 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2011, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.

Chapter 6 provides a comprehensive directory of partnering and M&A activity during 2011. The deals are listed by company A-Z, and industry sector, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the resources necessary to make research and understand the M&A deals of 2011.

Benefits

M&A Yearbook 2012 provides the reader with the following key benefits:

In-depth understanding of dealmaking trends in 2011
Comprehensive access to over 600 M&A deals entered into by the world’s biopharma companies during 2011
Detailed access to actual M&A deals and contracts entered into by the leading fifty bigpharma companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope

M&A Yearbook 2012 is intended to provide the reader with an in-depth understanding and access to M&A trends and structure of deals entered into by leading companies worldwide.

M&A Yearbook 2012 includes:

Trends in dealmaking in the biopharma industry
Analysis of M&A deal structure
Comprehensive directory of M&A deals in 2011
Links to online access to over 600 M&A deals
The leading M&A deals by value in 2011
Most active M&A dealmakers during 2011
In M&A Yearbook 2012, the M&A deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type
Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand.

Executive Summary
 
 Chapter 1 – Introduction
 
 Chapter 2 – Overview of M&A activity in 2011
 
 3.1. Introduction
 3.2. M&A deals of 2011
 3.2.1. M&A activity by volume
 3.2.2. M&A activity by deal dollars
 3.3. Key M&A deals of 2011 – The top 10
 3.3.1. Express Scripts – Medco Health Solutions: Acquisition agreement for Medco Health Solutions
 3.3.2. Johnson & Johnson – Synthes: Acquisition agreement for Synthes
 3.3.3. Takeda – Nycomed: Acquisition agreement for Nycomed
 3.3.4. Gilead Sciences – Pharmasset: Acquisition agreement for Pharmasset
 3.3.5. Danaher – Beckman Coulter: Acquisition agreement for Beckman Coulter
 3.3.6. Teva – Cephalon: Acquisition agreement for Cephalon
 3.3.7. DuPont – Danisco: Acquisition agreement for Danisco
 3.3.8. Kinetic Concepts – Apax Partners: Acquisition agreement for Kinetic Concepts
 3.3.9. PPD – Carlyle Group – Hellman & Friedman: Acquisition agreement for PPD
 3.3.10. Thermo Fisher Scientific – Phadia: Acquisition agreement for Phadia
 3.4. Bigpharma M&A deals of 2011
 3.5. M&A deals by industry sector in 2011
 Chapter 3 – Most active dealmakers in 2011
 
 3.1. Introduction
 3.2. M&A – most active in 2011
 Chapter 4 – Top deals by value in 2011
 
 4.1. Introduction
 4.2. Top M&A deals in 2011
 Chapter 5 – Bigpharma partnering in 2011
 
 5.1. Introduction
 5.2. Bigpharma partnering by industry sector
 5.3. Bigpharma partnering by deal type
 5.4. Bigpharma partnering by stage of development
 5.5. Bigpharma partnering by therapy area
 5.6. Bigpharma deal directory 2011
 Abbott
 Actavis
 Alcon Labs
 Allergan
 Amgen
 Apotex
 Astellas
 AstraZeneca
 Baxter International
 Bayer
 Biogen Idec
 Boehringer Ingelheim
 Bristol-Myers Squibb
 Celgene
 Cephalon
 Chugai
 CSL
 Daiichi Sankyo
 Dainippon Sumitomo
 Eisai
 Eli Lilly
 Forest Laboratories
 Genzyme
 Gilead Sciences
 GlaxoSmithKline
 Hospira
 Johnson & Johnson
 Kyowa Hakko Kirin
 Lundbeck
 Menarini
 Merck & Co
 Merck KGaA
 Mitsubishi Tanabe
 Mylan
 Novartis
 Novo Nordisk
 Nycomed Pharma
 Otsuka
 Pfizer
 Roche
 Sanofi
 Servier
 Shionogi
 Shire
 Stada
 Takeda
 Teva
 UCB
 Warner Chilcott
 Watson
 Chapter 6 – M&A directory 2011
 
 6.1. Introduction
 6.2. By company A-Z
 6.3. By industry sector
 Bigpharma
 Pharmaceuticals
 Biotechnology
 Diagnostics
 Drug delivery
 Medical device
 Consumer health
 Specialty pharma
 Generic pharma
 Agricultural
 Animal health
 Research tools
 Service company
 Chapter 7 – Submitting Opportunities to Potential Partners
 
 7.1. Introduction
 7.2. How to submit an opportunity
 7.3. Opportunity submission template
 7.4. Sending emails
 7.5. Face to face at partnering events
 7.6. Online submission forms
 7.7. Forthcoming partnering events in 2012
 Chapter 8 – Resources
 
 Further information
 Methodology
 About Wildwood Ventures
 Current Partnering
 Current Agreements
 Recent titles from CurrentPartnering
 Order Form – Reports
 Order Form – Partnering Agreements Company Profiles